

**INDEX**

# Subject index to volume 29

**A**

Abduction, 180, 182, 184  
 Adduction, 178, 180  
 Aberrations  
     comparison of higher order in low to moderate myopia, 33  
     measurement of wavefront, 34  
 Abscess  
     postsurgical suppurative scleral, 194  
 Achromatic perimetry, 64  
 ADH. *See* alcohol dehydrogenase  
 Adrenergic response  
     induced by cortocosteroid, 10  
 Advanced Glaucoma Intervention Study,  
     implications on clinal practice, 99, 105,  
     on the protective role of IOP lowering, 169  
 Age-related macular degeneration  
     as a cause of blindness, 47  
 AGIS. *See* Advanced Glaucoma Intervention Study  
 AIDS  
     ocular toxoplasmosis in patients with, 92  
 AIGS. *See* Association of International Glaucoma Societies  
 AION. *See* ischemic optic neuropathy  
 Alcohol dehydrogenase  
     use in management of alcohol-induced optic neuropathy, 189  
 Alstrom syndrome, 95  
 Alstrom's disease, 196  
 Amaurosis, 161  
 Amblyopia, 46, 141, 179  
 Amphotericin B, 28  
 Amvisc Plus, 12  
 Aniridia, 141–142  
 Ankyloblepharon, 146  
 Anophthalmos, 145  
 Antifibrotic agent  
     factors to consider when using, 86  
 Anti-Koch's treatment  
     as a cause of optic neuropathy (*editorial*), 158  
     *See also* ethambutol-induced optic neuropathy  
 Aplasia, 184  
 Applanation tonometry  
     *See* Goldmann applanation tonometry  
 Apoptosis  
     in human retinal pigment epithelium cells *in vitro*, 6

Apoptotic cells  
     quantification of, 9  
 Arachnoid villi, 164  
 Argon laser  
     sequential argon-YAG compared with Nd:YAG, 132  
*Aspergillus flavus*, 26–28  
 Aspiration-biopsy cytology, 176–177  
 Association of International Glaucoma Societies  
     recommendations on assessment of optic nerve and management of glaucoma, 77  
 Astigmatism, 97  
 Atovaquone, 92  
 Atrophy  
     macular, in Usher syndrome, 195  
     of the retinal pigment epithelium and choriocapillaries in Usher syndrome, 195  
     optic, in methanol-induced neuropathy, 190  
 Atypical optic neuritis, 162

**B**

BAER. *See* Brainstem-auditory-evoked response  
 Bardet-Biedl syndrome  
     a case of, 94  
     associated with deafness and pigmentary retinopathy, 196  
     diagnostic criteria for, 95–96  
     differential diagnoses, 95  
     management of, 97  
     manifestations of, 94, 95  
     ophthalmologic problems in patients with, 97  
 BBS. *See* Bardet-Biedl syndrome  
 Bevel down technique, 119  
 Biemond II syndrome, 95  
 Blindness  
     alcohol-induced, 190  
     causes of, 47  
     DOH Prevention of Blindness Program, 44, 45  
     childhood, 47, 141  
     in systemic lupus erythematosus, 18  
     prevalence in the Philippines, 43  
     results of first national blindness survey, 45  
     Second National Blindness Survey, 44  
 Brachydactyly,  
     in Möbius sequence, 96–97  
 Brainstem-auditory-evoked response, 181

## C

*Candida parasilopsis*, 26–28  
Capsulorhexis, 121  
Cataract  
    blindness, 46–47  
    brunescent, 119  
    childhood, 141  
    chopping techniques for brunescent, 118–121  
    dense/hard, 118  
    familial, 141  
    idiopathic, 141–142  
    in infancy, 141  
    posterior subcapsular, 17  
    prevalence of operable, 47  
    profile of childhood cases at Philippine General Hospital, 140  
    secondary, 142  
    surgery/surgery rate, 12, 46–47, 122  
    case of postsurgical scleritis, 193  
        *See also* surgically induced necrotizing scleritis after cataract surgery  
Cat's eye reflex, 136–137  
CCT. *See* central corneal thickness  
Central corneal thickness  
    correlation with IOP among Filipinos, 79  
    predictive factor in the development of primary open-angle glaucoma, 100  
Central nervous system  
    abnormalities, 142  
Central-retinal-vein occlusion, 161  
Central serous chorioretinopathy  
    characteristic, 7  
    epinephrine-induced, 10  
    mechanism of cause, 7  
    prevalence, 7  
Cerebral palsy, 142  
Chipping technique, 133  
Chopping technique, 119  
CIGTS. *See* Collaborative Initial Glaucoma Treatment Study  
Ciliary body ablation in end-stage glaucoma, 172  
Coats' disease, 149  
Cockayne's syndrome, 196  
Collaborative Initial Glaucoma Treatment Study, 65, 99, 103  
Congenital  
    anomalies, 150  
    cataract, 141  
    coloboma of the eyelids, 146  
    deafness, 195  
    eye defects, 145  
    heart defects, 142  
    neurosensory deafness, 196

Congenital rubella syndrome  
    as a cause of cataract, 142  
Conjunctiva  
    melanoma of, 147  
Corneal  
    birefringence, 70  
    endothelial edema, 132  
    injury, 15  
    scar, 47  
Cranial computed tomography  
    use in diagnosing methanol-induced optic neuropathy, 190  
Cranial nerve  
    involvement in Möbius sequence, 179–185  
Cryopexy  
    indications for use, 125  
Cryotherapy  
    in management of melanoma of the conjunctiva, 148  
Cryptophthalmos  
    a case of, 144  
    associated anomalies, 146  
    management of, 144, 146  
    pathogenesis of, 146  
CSCR. *See* central serous chorioretinopathy

## D

Demyelinating optic neuritis, 162  
Dexamethasone  
    for treatment of toxoplasmic retinochoroiditis, 92  
    in relation to apoptosis in human retinal pigment epithelium cells *in vitro*, 6  
Diabetic retinopathy, 47  
Diffuse depression, 161  
Diode-laser transscleral cyclophotocoagulation  
    single-setting treatment protocol, 171  
Disc edema, 161  
Diurnal intraocular-pressure, 168  
Diurnal curves  
    comparison of three-point and six-point determination, 167  
    peaks, 168  
Dolichoectasia of the internal carotid artery, 188  
Down syndrome, 140, 142  
Duovisc, 12

## E

Early Manifest Glaucoma Trial, 65, 99, 101  
Electromagnet  
    for extraction of metallic intraocular foreign bodies, 38–41  
Electrophysiologic testing, 189  
Elmycin, 26, 28

EMB. *See* ethambutol  
EMGT. *See* Early Manifest Glaucoma Trial  
Endothelial  
  cell count, 12  
  cell loss, 15  
Epiblepharon, 179–185  
Epicanthus, 184–185  
Epilepsy, 142  
Epinephrine  
  in apoptosis in human retinal pigment epithelium  
  cells *in vitro*, 6  
Error of refraction, 46, 47  
Esotropia in Möbius sequence, 179–185  
Ethambutol (*editorial*), 158  
Ethambutol-related optic neuropathy (*editorial*), 158  
Exotropia, 182–183  
Extracapsular cataract extraction, 193  
Extraepithelial proliferation  
  in malignant melanoma of the conjunctiva, 147  
Eye care  
  stages of programs in, 47  
  movement in the Philippines, 46  
Eye injuries  
  caused by metallic objects, 39

**F**

Facies, 179, 181, 183, 185  
Fibrovascularization  
  in orbital implants, 31  
Filtration surgery  
  causes of failure, 84  
Fine-needle aspiration biopsy  
  advantages of, 176  
  a valuable test for malignancy of orbital tumors, 175  
First national blindness survey, 45  
  *See also* blindness  
Flynn-Aird syndrome, 196  
FNAB. *See* fine-needle aspiration biopsy.  
Folic/folinic acid  
  in treatment of methanol-induced optic neuropathy, 192  
Formaldehyde, 191  
Formate, 191, 192  
Formic acid, 191  
Fraser syndrome, 146  
Friedreich's ataxia, 196  
Fungal keratitis  
  current treatment protocol for, 27  
  incidence, 27  
  *in vitro* evaluation of natamycin 5% suspension  
  for, 26  
*Fusarium solani*, 26–28  
Fusiform enlargement, 186, 188

**G**

Galactosemia  
  association with cataract, 141  
Glaucoma  
  advanced primary open-angle glaucoma 105  
  as a complication of corticosteroid treatment, 20  
  as one of the leading causes of blindness, 47  
  as ocular manifestation of systemic lupus erythematosus, 17  
  causes of failure of filtration surgery, 84  
  central corneal thickness and intraocular pressure correlation, 79  
  ciliary body ablation in end-stage, 172  
  detecting the disease early, 71  
  diurnal IOP curves, 167  
  filtering surgery, 103  
  gold standard in diagnosis, 64  
  Hemifield Test, 103  
  implications of randomized, controlled clinical trials, 99  
  neovascular, 174  
  normal-tension, 168  
  primary angle-closure, 132  
  primary open-angle, 100  
  progression of optic neuropathy in, 169  
  refractory, 171  
  resulting from expansion of perfluoropopane, 126  
  spectrum of damage in, 70  
  surgical management of, 84  
Glioma, 163  
Goldmann applanation tonometry  
  correlation with central corneal thickness, 79  
  *See also* glaucoma, central corneal thickness measurements confounded by central corneal thickness, 99

**H**

Hanhart syndrome, 185  
Helen Keller International, 44–45  
Hidden eye  
  a case of, 144  
  *See also* cryptophthalmos  
Histotoxic anoxia, 190  
Horizontal chopping technique, 119  
Hydroxyapatite, 22  
Hypogenitalism, 95, 97  
Hypoplasia, 184  
Hypotony, 171

**I**

ICA. *See* internal carotid artery  
Immunosuppressives  
  rapid response of patients with SINS to, 194

---

Implants  
  biocompatibility, 129  
  causes of migration, 22  
  characteristics of ideal, 22  
  extrusion, 22, 130  
  fibrovascularization, 31  
  freeze-dried human cancellous bone as orbital, 29  
  hollow polymethylmethacrylate, 21  
  hydroxyapatite 22, 30  
  ostrich eggshell implant as an onlay graft substitute for orbital blow-out fractures, 127

Infection  
  incidence with eggshell implant, 130

Infiltrative and compressive optic neuropathies, 162

Internal carotid artery, 186–188

Intracranial neoplasms, 160

Intraocular foreign body  
  penetrating injuries to the eye, 39  
  extraction using a low-cost electromagnet, 38–41  
  magnetic extraction of metallic, 39

Intraocular surgery, 80

Intraocular pressure  
  accurate measurement of, 80  
  beneficial effect of reduction in open-angle glaucoma, 99  
  control of, 131  
  fluctuation, 169  
  gold standard for clinical measurement of, 80  
  in diode-laser transscleral cyclophotocoagulation, 171  
  outcome measure in cataract surgery, 12  
  post trabeculectomy, 83  
  swings, 167

Intraocular-pressure curves  
  comparison of three-point and six-point diurnal measurements, 167

Intravenous corticosteroids, 159

Intravenous methylprednisolone, 159

IOFB. *See* intraocular foreign bodies

IOP. *See* intraocular pressure

Iridotomy, 131–132

Iris  
  bleeding, 132  
  perforation, 131  
  perforation-success rate, 132  
  pigmentation, 132

Ischemic optic neuropathy, 162

IVMP. *See* intravenous methylprednisolone

## J

Joint Tuberculosis Committee of the British Thoracic Society, 158

Jose Rizal Memorial Lecture, 42

## K

Keans-Sayne syndrome, 196

Keratitis  
  *See also* fungal keratitis  
  fungal, incidence, 27  
  fungal, treatment protocol, 27  
  prevention in cryptophthalmos, 144  
  in Möbius sequence, 179

Keratoconjunctivitis sicca, 17

## L

Lagophthalmos, 179, 180, 185

Lambanog, 190

LASEK. *See* laser-assisted subepithelial keratectomy

Laser-assisted subepithelial keratectomy, 37

Laser-diode transscleral cyclophotocoagulation  
  optimum dose, 174  
  single-setting treatment protocol, 171

Laser *in situ* keratomeleusis  
  comparison of wavefront-guided and standard laser in low to moderate myopia, 33–37

Laser iridotomy  
  comparison of Nd:YAG and sequential argon-YAG in Filipino eyes, 131  
  patency, 131–132  
  success rates, 132

Laser trabeculoplasty  
  in the Early Manifest Glaucoma Trial, 102,  
  in the Collaborative Interventional Glaucoma Treatment Study, 103

LASIK. *See* laser *in situ* keratomeleusis

Lattice degeneration  
  effect on anatomic outcome of pneumatic retinopexy, 124

Laurence Moon syndrome, 95

Leukocoria  
  bilateral, 148–149  
  in retinoblastoma, 136–137

Lid coloboma, 144

Lid edema, 162

Low vision, 46, 47

Lowe syndrome, 140, 142

LTP. *See* laser trabeculoplasty

Lupus erythematosus. *See* systemic lupus erythematosus

Lupus retinopathy. *See* systemic lupus erythematosus

## M

Maloney's supracapsular flip, 119

Melanoma of the conjunctiva  
  a case of, 147  
  differential diagnosis, 147  
  management of, 148  
  metastasis, 148

Meningiomas  
*See also* optic-nerve meningioma  
 of the optic-nerve, 160  
 pattern of intracranial extension, 164  
 sphenoid wing, 162

Metabolic acidosis, 191–192

Methanol  
 metabolism, 191  
 toxicity, 190–192  
 cause of bilateral optic neuropathy, 189

Methanol-induced bilateral optic neuropathy  
 a case of, 189  
 approaches to treatment, 191  
 pathophysiologic mechanism, 191–192

MFC. *See* minimum fungicidal concentration

MIC. *See* minimum inhibitory concentration

Microphthalmos, 145

Minimum fungicidal concentration, 26–28

Minimum inhibitory concentration, 26–28

Mitochondrial function  
 loss of, 191–192

Mitomycin-C  
 comparison of outcomes of trabeculectomies using concentrations of 0.4 mg/ml and 0.2 mg/ml, 83–87  
 for management of malignant melanoma of the conjunctiva, 148

Möbius sequence  
 absence of facial expression in, 179–184  
 cranial-nerve involvement in, 179–185  
 demographic and ocular findings in a series of Filipino patients, 181  
 diagnostic criteria, 179  
 strabismus presentations in Filipino patients, 178

Modified office-phasing procedure  
 in intraocular-pressure monitoring, 168, 169

**N**

Natracyn, 26–28

National Council on Blindness, 44

National Institutes of Health, 115

National Sight Plan, 44

Nd:YAG. *See* Neodymium: Yttrium-Aluminum-Garnet

Necrotizing scleritis, 193–194

Neodymium: Yttrium-Aluminum-Garnet  
 comparison with argon-YAG, 132  
 in ciliary body ablation, 172–173

Nerve-fiber analyzer  
*See also* Scanning laser polarimetry  
 diagnostic properties of the GDx 400, 66, 68  
 GDx 400, 66, 67, 70, 74–75  
 GDx number, 67

improving the accuracy of the GDx 400, 71  
 issues relating to GDx measurements, 69  
 issues relating to validity, 70  
 potential use as a screening tool, 66  
 receiver operating characteristics, 67  
 reliability analyses of, 73  
 reliability of the GDx 400, 73, 74

Neuro-ophthalmology, 158

Neuro-ophthalmology Club of the Philippines, 159

Neurofibromatosis in optic-nerve meningioma, 164

Neuroimaging, 162

Newborn screening, 141, 143

Norrie's disease, 150

Nuclear fragmentation, 118

Nuclear sclerosis, 121

Nyctalopia, 195

**O**

OAG. *See* open-angle glaucoma

Obesity, 97

Ocular hypertension. *See* glaucoma, intraocular pressure

Ocular Hypertension Treatment Study, 65, 99

Ocular toxoplasmosis  
 treatment during pregnancy, 88

Ocular ultrasonography, 149

OHTS. *See* Ocular Hypertension Treatment Study

Onchoceriasis, 47

ONH. *See* optic-nerve head.

Open-angle glaucoma  
 beneficial effect of IOP lowering in, 99  
*See also* glaucoma

Ophthalmic services, 47

Ophthalmologist-population ratio, 47

Optic atrophy  
 in systemic lupus erythematosus, 17  
 unexplained/caused by optic-nerve compression by the internal carotid artery, 186

Optic disc, 161

Optic-canal decompression, 164

Optic-disc  
 hyperemia, 190–192  
 progression, 101

Optic-nerve compression, 187–188

Optic-nerve meningioma  
 a close look, 160  
 distinction from glioma, 164  
 natural history, 164  
 treatment options, 164

Optic-nerve-damage progression  
 in glaucoma, 169

Optic-nerve head, 64

Optic-nerve-head stereophotography, 100

---

Optic-nerve-sheath  
meningiomas, 161  
meningiomas in children, 164  
thickening of, 163  
Optic-nerve vasculature, 161  
Optic Neuritis Treatment Trial, 159, 162  
Optic neuropathy  
case secondary to optic-nerve compression, 186  
anterior ischemic, 161  
secondary to fusiform enlargement, 188  
Orbital floor fractures, management of, 128  
Orbital implant. *See* implant  
Orbital inflammatory disease, 162  
Orbital lesions, 176–177  
Orbital mass, 136–137  
    *See also* retinoblastoma  
Orbital pseudotumor, 162  
Orbital tumors, 175  
    *See also* retinoblastoma, optic-nerve meningioma

## P

Palpebral fissure, 145  
PAM. *See* primary acquired melanosis  
Pars plana vitrectomy, 92, 124  
Periorbital edema, 17  
Peripheral anterior synechiae, 132  
Periphlebitis, 162  
Persistent hyperplastic primary vitreous, 149  
Phacoemulsification  
    chopping technique that attacks the posterior plate, 117  
    *See also* cataract  
Philippine Board of Ophthalmology, 45  
Philippine Optic Neuritis Treatment Trial, 159  
Photobiomodulation for treatment of alcohol-induced optic neuropathy, 192  
Photorefractive keratectomy, 37, 80  
PHPV. *See* persistent hyperplastic primary vitreous  
PlanoScan, 33  
PMMA, *See* polymethylmethacrylate  
Pneumatic retinopexy  
    causes of failure, 122, 123  
    potential complications, 126  
    use of intravitreal gas in, 123  
    compared with scleral buckling, 124  
POAG. *See* glaucoma.  
Poland-Möbius syndrome, 179  
Polymethylmethacrylate, 22  
    *See also* implants  
Polyethylene, 22, 30  
Positive predictive value, 70  
Postaxial hexadactyly, 97

Presbyopia, 47  
Primary acquired melanosis,  
    in melanoma of the conjunctiva, 147  
Proliferative vitreoretinopathy  
    failure of pneumatic retinopexy in eyes with, 122–126  
Proptosis, 136, 137, 162, 163  
Prostaglandin analogues, 103  
PSC. *See* cataract  
Pterygium, 193  
Ptosis, 178, 179, 182  
Pulmonary tuberculosis, 158  
PVR. *See* proliferative vitreoretinopathy.

## R

Radiologic appearance, 163  
Radiological examination, 128  
Reconstructive surgery, 146  
Refractive surgery, 34  
Refsum's disease, 196  
Renal dysfunction, 97  
Research  
    importance of (*editorial*), 115  
    output of developing countries (*editorial*), 116  
Retina, 190–192  
Retinal densitometry, 196  
Retinal detachment, 122  
Retinal dysplasia  
    a case of, 148  
    association with congenital anomalies and chromosomal abnormalities, 150  
    differential diagnosis in leukocoria, 150  
    pathogenesis of, 150  
Retinal nerve-fiber layer  
    assessment of, 67, 73, 74  
    birefringence, 70  
    changes in thickness, 74  
    “double-hump” profile, 70  
    measurement, 73, 74  
Retinal pigment epithelium  
    apoptosis in RPE cells *in vitro*, 6  
    atrophy of, 195  
    functions of, 7  
    in retinitis pigmentosa, 96  
    loss of pigment in Usher syndrome, 195  
Retinitis pigmentosa, 96, 195, 196  
Retinoblastoma  
    age of onset, 137  
    epidemiological and clinical patterns at the Philippine General Hospital, 136  
    familial incidence, 138  
    gender distribution, 137  
    incidence, 136, 138

malignancy of childhood, 149  
ocular manifestation at consultation, 137  
at onset, 136, 137  
tumor classification, 137

Retinopathy of prematurity, 149

Rhegmatogenous retinal detachment, 123

RNFL. *See* retinal nerve-fiber layer

RPE. *See* retinal pigment epithelium

Rubella  
congenital, 142  
as cause of cataract, 141–142

**S**

Sarcoidosis, 162

Scanning laser polarimetry, 67, 74  
*See also* nerve-fiber analyzer

Scleral buckling  
compared with pneumatic retinopexy, 124

Scleritis, 193

Section biopsy, 175–177

Sequential argon-Nd:YAG laser iridotomy, 133

Short wavelength automated perimetry, 71

Sight conservation and blindness prevention, 42

SINS. *See* surgically induced necrotizing scleritis

SLE. *See* systemic lupus erythematosus

SLEDAI. *See* Systemic Lupus Erythematosus Disease Activity Index

SLP. *See* scanning laser polarimetry

Sphenoid wing meningiomas, 162

Standard central corneal thickness, 80

Staphylococcus epidermidis, 145

Steinert chopper, 119

Stereotactic radiation, 166

Storz Millennium, 119

Strabismus, 46, 137, 178, 179, 193

Struthio camelus, 128

Subclavian-artery-supply-disruption-sequence theory, 184

Sulfonamides, 92

Surgical excision of sheath tumor, 164

Surgically induced necrotizing scleritis after cataract surgery, 193

SWAP. *See* short wavelength automated perimetry

Syndactyly, 183, 185

Syphilis, 162

Systemic lupus erythematosus  
estimated incidence, 18  
ocular manifestations of, 17–21

Systemic Lupus Erythematosus Disease Activity Index, 18

**T**

Talipes equinovarus, 178, 180, 183, 185

Thalidomide, 184

Third National Survey on Blindness, 47, 141

Tono-Pen, 80

Toxoplasma retinochoroiditis  
causes of, 89

Toxoplasmic retinochoroiditis  
recurrence of, 91

Trabeculectomy  
comparison of outcomes with 0.4 mg/ml and 0.2 mg/ml mitomycin concentrations, 83–87

Trachoma, 47

Transcleral cyclophotocoagulation  
single-setting treatment protocol for, 171–174  
treatment with corticosteroids, 194

Trichiasis, 184–185

Trisomy, 13, 150

TSCPC. *See* Transcleral cyclophotocoagulation

Tumor. *See* optic-nerve meningioma, retinoblastoma

**U**

Ultrasonic pachymetry, 79

Upper-respiratory-tract infection, 178, 181, 184

Urinary-tract infection, 181, 184

URTI. *See* upper-respiratory-tract infection

Usher syndrome  
a case of, 195  
diagnosis, 196  
fundus findings in, 195

UTI. *See* urinary-tract infection

Uveitis  
as a cause of secondary cataract, 142  
cause of posterior, 89

**V**

Varicella  
as a cause of childhood cataract, 140  
in Möbius sequence, 182

VEMs. *See* viscoelastic materials

Vertical cutting, 119

Viscoat, 12–15

Viscoelastic materials  
comparison of Amvisc Plus, Duovisc, and Viscoat on the corneal endothelium after cataract surgery, 12

Vision 2020, 48

Visual loss  
in optic-nerve meningioma, 161

Visual impairment  
causes of, 46, 47

---

---

Vitamin A  
    deficiency, cause of blindness, **47**  
    slows down decline in ERG responses, **97**  
Vitreous  
    persistent hyperplastic primary, **149**  
Vitritis, **121**

W  
Weiss syndrome, **95**

**X**  
X-linked recessive disorder, **142**  
Xerophthalmia, **47**

**Z**  
Zernike  
    coefficient, **36**  
    modes, **36–37**  
Zonulysis, **120**  
Zyoptix, **33–35**